Send feedback

AMPD2 p.Ser368Leu

c.1103C>T · rs1340521500 · VCV1033798

Uncertain significance Single submitter
Classification
Uncertain significance
ClinVar
Review
Single submitter ★☆☆☆
ClinVar · 1 submitter
AlphaMissense
likely pathogenic
0.9056 · ACMG-weighted
gnomAD v4.1
Rare
very rare (popmax 0.000254%, nfe)
Missense predictors
2/2 damaging
AlphaMissense, REVEL
Conditions
1
hereditary spastic paraplegia 63

Computational evidence

Protein change
AlphaMissense0.9056likely pathogenic
REVEL0.869moderately pathogenic-leaning
⇒ AlphaMissense and REVEL both call this damaging.
Splicing
SpliceAIΔ0.23acceptor gain, 17 bp away · raw score · deltas
Constraint at this position
ConservationphyloP 7.7GERP 2, phastCons 1
Regional constrainto/e 0.44unconstrained · MANE · 625 bp · p 2.1e-07 · regional, not allelic
Overall
CADD34.0PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean damaging — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

⚠ Isoform check: AlphaMissense numbered on a different transcript (AM S422L vs ClinVar S368L) — verify the residue.

Population frequency

gnomAD v4.1 · exomes + genomes
Grpmax group 0.000254% European (non-Finnish) · 3/1,179,862 alleles
Filtering AF 6.8e-05% ClinGen BA1/BS1 input FAF95, joint · FAF99 1.9e-05%
Overall 0.000248% 4/1,613,700 alleles · very rare
Ancestry group Frequency 1 in
Remaining individualsnot grpmax-eligible 0.0016% 62,478
European (non-Finnish)grpmax 0.000254% 393,287

Remaining individuals shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene
AMPD2
Protein
p.Ser368Leu
Coding
c.1103C>T
MANE Select
NM_001368809
dbSNP
rs1340521500
Type
single nucleotide variant
Location
chr1:109628105 (GRCh38)
Gene constraint
LOEUF 0.705 · pLI <0.01 (gnomAD)
Structure
AlphaFold pLDDT 81.28 · 5 PDB
Residue 368
an α-helix
Full AMPD2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

hereditary spastic paraplegia 63 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

For Autosomal recessive spastic paraplegia type 63 (Orphanet):

Inheritance
Autosomal recessive
Onset
Infancy

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/ampd2-p-ser368leu (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown